MGI Tech Singapore Pte, Ltd. (“MGI”), a company committed to building core tools and technology to lead life science, recently entered a research partnership with National Cancer Centre Singapore (“NCCS”) to facilitate comprehensive, multi-dimensional genomic profiling of Asian-prevalent cancers using MGI’s core DNBSEQ™ technology.
FDA pushes back decision on Zevra’s drug; Revance to raise $100M
Plus, news about Iovance Biotherapeutics, Nektar Therapeutics, Heidelberg Pharma, Vivoryon Therapeutics and Absci: FDA delays decision on Zevra Therapeutics’ rare disease drug: The FDA will
March 5, 2024